The Latest in Myelofibrosis
As genetic mutations for various cancer types are discovered, researchers have gone to work developing new medicines that inhibit those mutations. Such is the case with the JAK2 mutation now tied to myelofibrosis and scarring in the bone marrow. The first JAK2 inhibitor, Jakafi (ruxolitinib), is now approved in the U.S. and Europe. Dr. Tiziano Barbui, a myelofibrosis expert from Italy, explains how the new medicine can help.
Experts & Guests
Tiziano Barbui, M.D.
Professor, Ospedali Riuniti di Bergamo (Italy)Tiziano Barbui is Professor of Hematology and Scientific Director of the Research Foundation at Ospedali Riuniti di Bergamo (Italy). From 1981 until 2008 he was head of Department of Hematology at the Ospedali Riuniti di Bergamo. He has served as a chairman on the Subcommittee on Lupus Anticoagulant of the International Society of Thrombosis and Haemostasis, and as President of the... more >